[1] CLOETE L.Diabetes mellitus:an overview of the types,symptoms,complications and management[J].Nurs Stand,2022,37(1):61-66.
[2] TECK J.Diabetes-associated comorbidities[J].Prim Care,2022,9(2):275-286.
[3] JARLBORG P,JORNAYVAZ F R.Diabète pancréatoprive[Pancreatogenic diabetes][J].Rev Med Suisse,2022,18(784):1090-1095.
[4] VAZ DE CASTRO P A S,BITENCOURT L,DE OLIVEIRA CAMPOS J L,et al.Nephrogenic diabetes insipidus:a comprehensive overview[J].J Pediatr Endocrinol Metab,2022,35(4):421-434.
[5] COREGLIANO-RING L,GOIA-NISHIDE K,RANGELÉ B.Hypokalemia in diabetes mellitus setting[J].Medicina(Kaunas),2022,58(3):431.
[6] BARMAN S,SRINIVASAN K.Diabetes and zinc dyshomeostasis:can zinc supplementation mitigate diabetic complications?[J].Crit Rev Food Sci Nutr,2022,62(4):1046-1061.
[7] 都沙沙,蔡智国,杨琨,等.2型糖尿病伴牙周炎模型大鼠胰腺自噬及胰岛素相关基因蛋白的表达[J].中国组织工程研究,2022,26(29):4605-4610.
[8] 曾茗,盛兰兰,夏宇,等.基于模型荟萃分析5个SGLT2抑制剂在单用和联合用药治疗2型糖尿病的临床疗效[J].药学与临床研究,2022,30(3):200-206.
[9] LEGOUIS D,FAIVRE A,CIPPÀ P E,et al Renal gluconeogenesis:an underestimated role of the kidney in systemic glucose metabolism[J].Nephrol Dial Transplant,2022,37(8):1417-1425.
[10] NAKAMURA M,SATOH N,HORITA S,et al.Insulin-induced mTOR signaling and gluconeogenesis in renal proximal tubules:a mini-review of current evidence and therapeutic potential[J].Front Pharmacol,2022,13:1015204.
[11] SHARMA R,TIWARI S.Renal gluconeogenesis in insulin resistance:a culprit for hyperglycemia in diabetes[J].World J Diabetes,2021,12(5):556-568.
[12] SWE M T,PONGCHAIDECHA A,CHATSUDTHIPONG V,et al.Molecular signaling mechanisms of renal gluconeogenesis in nondiabetic and diabetic conditions[J].J Cell Physiol,2019,234(6):8134-8151.
[13] GRONDA EG,VANOLI E,IACOVIELLO M,et al.Renal effects of SGLT2 inhibitors in cardiovascular patients with and without chronic kidney disease:focus on heart failure and renal outcomes[J].Heart Fail Rev,2022,31:1-10.
[14] 文雅.SGLT-2抑制剂和GLP-1受体激动剂治疗2型糖尿病合并非酒精性脂肪肝疗效的Meta分析[D].南昌：南昌大学,2022.
[15] 王娜娜.SGLT2抑制剂治疗2型糖尿病合并心血管疾病的有效性和安全性的Meta分析[D].宜春：宜春学院,2022.
[16] WRIGHT E M.SGLT2 inhibitors:physiology and pharmacology[J].Kidney360,2021,2(12):2027-2037.
[17] VALLON V,THOMSON S C.Targeting renal glucose reabsorption to treat hyperglycaemia:the pleiotropic effects of SGLT2 inhibition[J].Diabetologia,2017,60(2):215-225.
[18] ZHUO M,PAIK J M,WEXLER D J,et al.SGLT2 inhibitors and the risk of acute kidney injury in older adults with type 2 diabetes[J].Am J Kidney Dis,2022,79(6):858-867.e1.
[19] WRIGHT A K,CARR M J,KONTOPANTELIS E,et al.Primary prevention of cardiovascular and heart failure events with SGLT2 inhibitors,GLP-1 receptor agonists,and their combination in type 2 diabetes[J].Diabetes Care,2022,45(4):909-918.
[20] TESAR∨ V.SGLT2 inhibitors in non-diabetic kidney disease[J].Adv Clin Exp Med,2022,31(2):105-107.
[21] KOVESDY C,SCHMEDT N,FOLKERTS K,et al.Predictors of cardio-kidney complications and treatment failure in patients with chronic kidney disease and type 2 diabetes treated with SGLT2 inhibitors[J].BMC Med,2022,20(1):2.
[22] 孙婧,苏爱梅.达格列净对老年2型糖尿病患者肾功能和钙磷代谢的影响[J].东南大学学报(医学版),2021,40(6):840-842.
[23] ZOU X,SHI Q,VANDVIK PO,et al.Sodium-glucose cotransporter-2 inhibitors in patients with heart failure:a systematic review and Meta-analysis[J].Ann Intern Med.2022,175(6):851-861.
[24] 杨蕊芳,刘昊凌.SGLT2抑制剂在糖尿病肾病中作用的研究进展[J].现代医学,2018,46(1):94-97.
[25] 张越,王丽宏.钠-葡萄糖共转运蛋白2抑制剂在改善胰岛素抵抗和胰岛β细胞功能方面的研究进展[J].临床内科杂志,2023,40(3):213-215.
[26] 王威.SGLT2抑制剂在非酒精性脂肪性肝病防治中的作用及机制研究[D].南昌：南昌大学,2020.
[27] 吴娇娇.SGLT-2抑制剂对T2DM患者内脏脂肪面积的影响[D].芜湖：皖南医学院,2022.
[28] 李萌,庞立香,马茜茜,等.钠-葡萄糖共转运蛋白2抑制剂(SGLT2-抑制剂)对糖尿病的机制和治疗研究综述[J].中国比较医学杂志,2023,33(8):127-132.
[29] REN Q,GONG S,HAN X,et al.Hereditary renal glycosuria,diabetes and responses to SGLT2 inhibitor[J].J Diabetes,2022,14(3):216-220.
[30] 白晶,陆朋,董瑞鸿.卡格列净联合吡格列酮治疗2型糖尿病的临床研究[J].现代药物与临床,2022,37(5):1052-1055.
[31] BAKRIS G,OSHIMA M,MAHAFFEY K W,et al.Effects of canagliflozin in patients with baseline eGFR<30 ml/min per 1.73 m2:subgroup analysis of the randomized CREDENCE trial[J].Clin J Am Soc Nephrol,2020,15(12):1705-1714.
[32] 曹雨琛,李成强,刘鉴颖,等.SGLT2抑制剂达格列净对糖尿病肾病的保护机制研究[J].北华大学学报(自然科学版),2022,23(1):64-69.
[33] 陈玉英,李晓冬,汤云昭,等.不同剂量卡格列净联合二甲双胍治疗2型糖尿病临床疗效的Meta分析[J].中国全科医学,2022,25(15):1888-1896,1905.
[34] 陈军.SGLT-2i(卡格列净)与ARB(厄贝沙坦)联用治疗早期糖尿病肾病患者的疗效观察[D].新疆乌鲁木齐:新疆医科大学,2021.
[35] 孙云静,王林青,张亚静,等.基于P38 MAPK信号通路探讨达格列净对老年2型糖尿病伴慢性心力衰竭患者心功能、主要心血管不良事件发生风险的影响[J].中国糖尿病杂志,2022,30(7):501-506.
[36] CHERNEY D Z I,DEKKERS C C J,BARBOUR S J,et al.Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease(DIAMOND):a randomised,double-blind,crossover trial[J].Lancet Diabetes Endocrinol,2020,8(7):582-593.
[37] 曲建昌,弓月,王彤,等.达格列净联合二肽基肽酶4抑制剂和二甲双胍治疗血糖控制不佳2型糖尿病的效果分析[J].中国医药,2021,16(6):857-860.
[38] 高梅,姜冲.达格列净联合利拉鲁肽对肥胖型2型糖尿病患者糖脂代谢、胰岛素功能、血糖波动的影响[J].临床医学研究与实践,2022,7(18):32-35.
[39] ROSSING P,INZUCCHI S E,VART P,et al.Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure:pooled analysis of the DAPA-CKD and DAPA-HF trials[J].Lancet Diabetes Endocrinol,2022,10(1):24-34.
[40] 哈斯格日乐.达格列净对胰岛功能受损的2型糖尿病患者的疗效观察[D].通辽:内蒙古民族大学,2022.
[41] 韦琬,郭延云,杜益君,等.恩格列净对2型糖尿病合并高血压患者血压变异性和左心室质量指数的影响[J].中华糖尿病杂志,2022,14(4):329-336.
[42] 胡彪.恩格列净对2型糖尿病患者血压影响的研究[D].南昌：南昌大学,2022.
[43] 史丽,胡婷婷,李红,等.恩格列净对血糖波动糖尿病小鼠肾损伤的影响及其机制研究[J].中国现代医学杂志,2022,32(4):40-44.
[44] 牛尚梅,宋潇萌,张晓杰,等.恩格列净联合二甲双胍治疗2型糖尿病的效果[J].中国医药导报,2022,19(6):76-80.
[45] 陈显建,商永光.恩格列净治疗2型糖尿病不良反应的Meta-分析[J].药物评价研究,2019,42(1):159-165.
[46] 邱建美.恩格列净对肥胖2型糖尿病患者脂代谢及内脏脂肪面积的影响[D].邯郸：河北工程大学,2022. |
